Danaher Grabs Molecular Diagnostics Co. In $4B Cash Deal

Law360, New York (September 6, 2016, 6:00 PM EDT) -- Science and technology giant Danaher Corp. said Tuesday that it would buy California-based molecular diagnostics company Cepheid in a deal valued at about $4 billion, including debt and net cash on hand, marking Danaher's first major move after its July spinoff of certain business units.

Danaher is set to shell out $53 per share in cash to add Cepheid to its diagnostics segment, where it will join and complement Beckman Coulter, Leica Biosystems and the science and technology company's Radiometer businesses, according to Tuesday's statement. Cepheid makes molecular systems and tests that can help doctors diagnose diseases, the statement said....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!